All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

New Grant Funds First-of-Its-Kind Gene Therapy to Treat Aggressive Brain Cancer

March 21st 2025

The California Institute for Regenerative Medicine has awarded a $6 million grant to USC investigators pioneering a new genetic therapy to treat glioblastoma.

Bioengineered Bone Marrow Model Reveals Potential New Strategies for Osteosarcoma Metastasis Control

March 21st 2025

R. Lor Randall, MD, FACS, discusses the development of a bone marrow matrix to study osteosarcoma and the model’s mechanisms of metastasis control.

NMPA Grants Conditional Approval to Tazemetostat for EZH2-Mutant R/R Follicular Lymphoma

March 21st 2025

China’s NMPA has granted conditional approval to the EZH2 inhibitor tazemetostat for patients with relapsed/refractory EZH2-mutated follicular lymphoma.

PLN-101095/Pembrolizumab Has Early Activity in ICI-Refractory Advanced Solid Tumors

March 21st 2025

PLN-101095 plus pembrolizumab was safe and active in immune checkpoint inhibitor–refractory advanced solid tumors.

Improving Outcomes for Patients With Anal Cancer By Raising Awareness

March 21st 2025

For Anal Cancer Awareness Day, Sheela Rao, MBBS, MD, FRCP, discusses present and upcoming treatment strategies, unmet needs, and the future of the field.

Emerging ADCs, Biomarker-Driven Treatments, and Diagnostic Advancements Take Center Stage at the SGO Annual Meeting

March 21st 2025

Experts reflect on pivotal data, emerging agents, and highly-anticipated trends in gynecologic cancer care discussed during the 2025 SGO Annual Meeting.

AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Based Insights

March 21st 2025

Joshua Feinberg, MD, discusses the role of the Scout AI platform in aiding trial matching and treatment selection in oncology.

First-Line Atezolizumab Is Suitable in Platinum-Based Chemotherapy Ineligible mUC

March 21st 2025

Real-world data showed that atezolizumab provided a benefit and was safe in patients with platinum-ineligible mUC and high comorbidities/functional status.

FDA Approves PSMA PET Imaging Agent TLX007-CDx for Prostate Cancer

March 20th 2025

The FDA has approved TLX007-CDx as an imaging agent in select patients with prostate cancer.

Patient Guidance and Care Drives McCann’s Passion as a Woman in Oncology

March 20th 2025

Kelly E. McCann, MD, discusses mentorship in oncology and the importance of guiding patients with breast cancer through their treatment journey.

Comprehensive Communication Regarding CRC Surgery and Postoperative Complications Is Crucial

March 20th 2025

Andreas M. Kaiser, MD, discusses strategies to reduce postoperative complications and determine surgical eligibility in patients with CRC.

Intersectionality, Leadership, and Empowerment Drive Jagsi as a Woman in Oncology

March 20th 2025

Reshma Jagsi, MD, DPhil, highlights her journey to becoming a radiation oncologist and the nuances of intersectionality as a woman in oncology.

Roswell Park Named One of Only 37 Optum Cancer Centers of Excellence for Adult and Pediatric Patients

March 20th 2025

Roswell Park Comprehensive Cancer Center has been recognized as a Center of Excellence for both adult and pediatric cancer treatment by Optum.

PEP-010 Wins FDA Orphan Drug Designation in Metastatic Pancreatic Cancer

March 20th 2025

PEP-010 has been granted an orphan drug designation by the FDA for the treatment of patients with metastatic pancreatic cancer.

FDA Grants Fast Track Designation to Azer-Cel for R/R DLBCL

March 20th 2025

The FDA granted fast track designation azercabtagene zapreleucel for relapsed/refractory diffuse large B-cell lymphoma.

IL-Agonist NKTR-255 Shows Ability to Enhance Responses to CAR T-Cell Therapy in R/R LBCL

March 20th 2025

Sairah Ahmed, MD, discusses findings from a phase 2 trial of NKTR-255 after CD19-directed CAR T-cell therapy in relapsed/refractory LBCL.

PARP Inhibitor and ARPI Combinations Are at the Forefront of Investigations in mCRPC

March 20th 2025

Monica Chatwal, MD, details new research shedding light on PARP/ARPI combinations in mCRPC, especially in BRCA-mutated and HRR gene–altered populations.

Avapritinib Leads a Charge of Novel Targeted Therapies for Indolent Systemic Mastocytosis

March 19th 2025

Tsewang Tashi, MD, discusses the efficacy and tolerability of targeted therapies like avapritinib for patients with indolent systemic mastocytosis.

Brentuximab Vedotin Combo Adds Another Targeted Option Beyond CD19/CD20 in R/R LBCL

March 19th 2025

Grzegorz S. Nowakowski, MD, discusses the FDA approval of brentuximab vedotin plus lenalidomide and rituximab for relapsed/refractory LBCL.

FDA Approves Pembrolizumab Plus Trastuzumab/Chemo for PD-L1+, HER2+ Gastric/GEJ Adenocarcinoma

March 19th 2025

The FDA approved pembrolizumab, trastuzumab, and chemotherapy for HER2-positive, PD-L1–positive gastric/GEJ adenocarcinoma.